<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417778</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-417-4048</org_study_id>
    <secondary_id>2017-000156-25</secondary_id>
    <nct_id>NCT03417778</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function</brief_title>
  <official_title>A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of Filgotinib in Subjects With Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics (PK) of filgotinib
      and its metabolite, GS-829845, in participants with varying degrees of impaired hepatic
      function relative to matched, healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) for Filgotinib and GS-829845</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve Extrapolated to Infinite Time (AUCinf) for Filgotinib and GS-829845</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Filgotinib and GS-829845.</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 120 hours postdose on Day 1</time_frame>
    <description>Cmax is maximum observed concentration of drug in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Experiencing Adverse Events</measure>
    <time_frame>Up to 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Graded Clinical Chemistry or Hematology Laboratory Abnormalities</measure>
    <time_frame>Up to 31 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>100 mg tablet administered orally</description>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Eligible individuals will be male and nonpregnant, nonlactating females, aged 18 to 70
             years (inclusive), body mass index (BMI) between 18 and 36 kg/m^2 (inclusive), with
             either impaired hepatic function or normal hepatic function.

          -  Individuals will be current nonsmokers (no use of tobacco, nicotine-containing, or
             tetrahydrocannabinol (THC)-containing products within the last 14 days).

          -  Individuals with hepatic impairment will be categorized by the Child-Pugh-Turcotte
             (CPT) classification system indicating hepatic impairment as follows:

               -  Class A (mild): CPT score 5-6

               -  Class B (moderate): CPT score 7-9

               -  Class C (severe): CPT score 10-15

          -  Hepatic impairment must have been stable during the 3 months (90 days) prior to study
             drug. Each individual in the control group will be matched to a individual with
             impaired hepatic function by age (± 10 years), gender, and body mass index (± 15%).

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd.</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

